AIM: To evaluate the presence and cross-reactive antibodies against hypervariable region 1 (HVR1) in hepatitis C virus (HCV) infected patients and its relationship with the progression of the disease. METHODS: Sixteen representative HVR1 proteins selected from a unique set of 1600 natural sequences were used to semiquantitate the cross-reactivity of HVR1 antibodies in the sera of HCV patients. Fifty-five chronic HCV patients including 23 with asymptomatic mild hepatitis, 18 with chronic hepatitis and 16 with liver cirrhosis patients were studied. RESULTS: The degree of the cross-reactivity of anti-HVR1 antibodies in 23 patients with mild asymptomatic hepatitis was 3.09 ± 2.68, which was significantly lower than in those with chronic hepatitis (5.44 ± 3.93, P < 0.05) and liver cirrhosis (7.44 ± 3.90, P < 0.01). No correlation was observed between the broadness of the cross-reactivity anti-HVR1 antibodies and patient's age, infection time, serum alanine aminotransferase activity, or serum HCV-RNA concentration. It was the breath of cross-reactivity rather than the presence of anti-HVR1 antibody in HCV sera that was associated with the progression of liver disease. CONCLUSION: The broadly cross-reactive HVR1 antibodies generated in natural HCV patients can not neutralize the virus, which results in persistent infection in patients with chronic hepatitis.
AIM: To evaluate the presence and cross-reactive antibodies against hypervariable region 1 (HVR1) in hepatitis C virus (HCV) infectedpatients and its relationship with the progression of the disease. METHODS: Sixteen representative HVR1 proteins selected from a unique set of 1600 natural sequences were used to semiquantitate the cross-reactivity of HVR1 antibodies in the sera of HCVpatients. Fifty-five chronic HCVpatients including 23 with asymptomatic mild hepatitis, 18 with chronic hepatitis and 16 with liver cirrhosispatients were studied. RESULTS: The degree of the cross-reactivity of anti-HVR1 antibodies in 23 patients with mild asymptomatic hepatitis was 3.09 ± 2.68, which was significantly lower than in those with chronic hepatitis (5.44 ± 3.93, P < 0.05) and liver cirrhosis (7.44 ± 3.90, P < 0.01). No correlation was observed between the broadness of the cross-reactivity anti-HVR1 antibodies and patient's age, infection time, serum alanine aminotransferase activity, or serum HCV-RNA concentration. It was the breath of cross-reactivity rather than the presence of anti-HVR1 antibody in HCV sera that was associated with the progression of liver disease. CONCLUSION: The broadly cross-reactive HVR1 antibodies generated in natural HCVpatients can not neutralize the virus, which results in persistent infection in patients with chronic hepatitis.
Authors: Donghui Zhou; Xiaofeng Fan; De Tan; Yanjuan Xu; John E Tavis; Adrian M Di Bisceglie Journal: J Virol Methods Date: 2007-01-08 Impact factor: 2.014
Authors: Maria G Isaguliants; Anders Widell; Shumin M Zhang; Anna Sidorchuk; Michael Levi; Valerii D Smirnov; Teresa Santantonio; Helmut M Diepolder; Gerd R Pape; Erik Nordenfelt Journal: J Med Virol Date: 2002-02 Impact factor: 2.327
Authors: Hui Li; Brian J McMahon; Susan McArdle; Dana Bruden; Daniel G Sullivan; Dave Shelton; Heike Deubner; David R Gretch Journal: Virology Date: 2008-03-17 Impact factor: 3.616
Authors: Pei Zhang; Lilin Zhong; Evi Budo Struble; Hisayoshi Watanabe; Alla Kachko; Kathleen Mihalik; Maria Luisa Virata; Harvey J Alter; Stephen Feinstone; Marian Major Journal: Proc Natl Acad Sci U S A Date: 2009-04-20 Impact factor: 11.205